Avalyn Pharma (NASDAQ:AVLN) Upgraded to “Moderate Buy” at Raymond James Financial

Raymond James Financial upgraded shares of Avalyn Pharma (NASDAQ:AVLN) to a moderate buy rating in a research report report published on Friday morning,Zacks reports.

Several other brokerages also recently commented on AVLN. Weiss Ratings began coverage on Avalyn Pharma in a research note on Thursday, August 13th. They set a “sell (d+)” rating for the company. Wall Street Zen cut shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Finally, Morgan Stanley lifted their target price on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.

Avalyn Pharma Price Performance

Shares of AVLN opened at $28.13 on Friday. Avalyn Pharma has a one year low of $24.15 and a one year high of $40.17. The firm has a market capitalization of $1.25 billion and a P/E ratio of -1.23. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average price is $33.49.

Avalyn Pharma (NASDAQ:AVLN) last issued its earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.05. On average, analysts expect that Avalyn Pharma will post -3.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avalyn Pharma

Several hedge funds and other institutional investors have recently modified their holdings of AVLN. State Street Corp acquired a new stake in Avalyn Pharma in the 2nd quarter valued at $10,501,000. Braidwell LP purchased a new stake in Avalyn Pharma in the 2nd quarter valued at about $26,382,000. Montanova Capital LLC purchased a new stake in shares of Avalyn Pharma during the second quarter valued at approximately $82,402,000. Finally, Bank of New York Mellon Corp bought a new position in Avalyn Pharma in the 2nd quarter valued at $1,321,000.

About Avalyn Pharma

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.